Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

P493-6 treated with KJ-Pyr-9 and/or Doxycycline

ABSTRACT: In a fluorescence polarization screen for MYC-MAX interaction, we have identified a novel small molecule inhibitor of MYC, KJ-Pyr-9, from a Kröhnke pyridine library. The Kd of KJ-Pyr-9 for MYC in vitro is 6.5 ± 1.0 nM as determined by backscattering interferometry; KJ-Pyr-9 also interferes with MYC-MAX complex formation in the cell as shown in a protein fragment complementation assay. KJ-Pyr-9 specifically inhibits MYC-induced oncogenic transformation in cell culture; it has no or only weak effects on the oncogenic activity of several unrelated oncoproteins. KJ-Pyr-9 preferentially interferes with the proliferation of MYC-overexpressing human and avian cells and specifically reduces the MYC-driven transcriptional signature. In vivo, KJ-Pyr-9 effectively blocks the growth of a xenotransplant of MYC-overexpressing  human cancer cells. 4 treatment groups analyzed in triplicate: no treatment(control), 20uM KJ-Pyr-9, 0.1ug/mL doxycycline and KJ-Pyr-9 in combination with doxycycline

ORGANISM(S): Homo sapiens

SUBMITTER: Jonathan Hart 

PROVIDER: E-GEOD-58168 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Inhibitor of MYC identified in a Kröhnke pyridine library.

Hart Jonathan R JR   Garner Amanda L AL   Yu Jing J   Ito Yoshihiro Y   Sun Minghao M   Ueno Lynn L   Rhee Jin-Kyu JK   Baksh Michael M MM   Stefan Eduard E   Hartl Markus M   Bister Klaus K   Vogt Peter K PK   Janda Kim D KD  

Proceedings of the National Academy of Sciences of the United States of America 20140811 34

In a fluorescence polarization screen for the MYC-MAX interaction, we have identified a novel small-molecule inhibitor of MYC, KJ-Pyr-9, from a Kröhnke pyridine library. The Kd of KJ-Pyr-9 for MYC in vitro is 6.5 ± 1.0 nM, as determined by backscattering interferometry; KJ-Pyr-9 also interferes with MYC-MAX complex formation in the cell, as shown in a protein fragment complementation assay. KJ-Pyr-9 specifically inhibits MYC-induced oncogenic transformation in cell culture; it has no or only wea  ...[more]

Similar Datasets

Transcriptomics P493-6 treated with KJ-Pyr-9 and/or Doxycycline
2014-08-25 | GSE58168 | GEO
Genomics,Multiomics Homo sapiens
| PRJNA251417 | ENA
Transcriptomics Sirt1, p53 and p38MAPK are crucial regulators of detrimental phenotypes of ESCs with Max expression ablation
2012-08-28 | GSE37917 | GEO
Transcriptomics Sirt1, p53 and p38MAPK are crucial regulators of detrimental phenotypes of ESCs with Max expression ablation
2012-08-28 | E-GEOD-37917 | biostudies-arrayexpress
Transcriptomics Knock-in of PIK3CA-H1047R into MCF-10A
2015-01-19 | E-GEOD-63452 | biostudies-arrayexpress
Transcriptomics Global transcriptional responses to KI-MS2-008 treatment and Myc inactivation via doxycycline addition
2019-03-14 | GSE107222 | GEO
Proteomics MAX-mutant small cell lung cancers exhibit impaired activities of MGA-dependent ncPRC1.6.
2021-09-22 | PXD017658 | Pride
Genomics CUT&RUN comparing occupancy of MAX, MNT, MYC in MAX WT and KO B220+ cells
2019-06-20 | GSE132967 | GEO
Transcriptomics Functional interplay between c-Myc and Max in B lymphocyte differentiation
2018-08-20 | GSE115915 | GEO
Transcriptomics Ubiquitin-dependent turnover of MYC promotes loading of the PAF complex on RNA Polymerase II to drive transcriptional elongation (RNA-seq)
2016-01-04 | E-GEOD-70000 | biostudies-arrayexpress